NASDAQ:CCXI

ChemoCentryx Stock Forecast, Price & News

$56.38

-2.91 (-4.91 %)

(As of 01/27/2021 12:00 AM ET)

Add

Compare

Today's Range

$53.83

Now: $56.38▼

$58.41

50-Day Range

$57.35

MA: $61.46▼

$65.16

52-Week Range

$30.72

Now: $56.38▼

$67.43

Volume808,471 shs

Average Volume549,256 shs

Market Capitalization$3.90 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.7

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.

MarketRank^™

Overall MarketRank^™

1.57 out of 5 stars

Medical Sector

151st out of 1,926 stocks

Pharmaceutical Preparations Industry

74th out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
ChemoCentryx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $77.13, ChemoCentryx has a forecasted upside of 36.8% from its current price of $56.38.
Amount of Analyst Coverage
ChemoCentryx has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
ChemoCentryx has received 318 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ChemoCentryx has received 281 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ChemoCentryx has received 53.09% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote “Outperform” if you believe CCXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ChemoCentryx does not currently pay a dividend.
Dividend Growth
ChemoCentryx does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ChemoCentryx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,624,872.00 in company stock.
Percentage Held by Insiders
Only 9.30% of the stock of ChemoCentryx is held by insiders.
Percentage Held by Institutions
80.67% of the stock of ChemoCentryx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for ChemoCentryx are expected to decrease in the coming year, from ($0.72) to ($1.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ChemoCentryx is -84.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ChemoCentryx is -84.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ChemoCentryx has a P/B Ratio of 49.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:CCXI

Previous Symbol

CUSIP16383L10

CIK1340652

Webwww.chemocentryx.com

Phone650-210-2900

Employees82

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.05

Current Ratio10.12

Quick Ratio10.12

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$36.13 million

Price / Sales108.00

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.14 per share

Price / Book49.46

Profitability

EPS (Most Recent Fiscal Year)($0.98)

Net Income$-55,490,000.00

Net Margins-58.10%

Return on Equity-17.23%

Return on Assets-11.07%

Miscellaneous

Outstanding Shares69,208,000

Market Cap$3.90 billion

Next Earnings Date3/9/2021 (Estimated)

OptionableOptionable

$56.38

-2.91 (-4.91 %)

(As of 01/27/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

How has ChemoCentryx's stock been impacted by Coronavirus?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has increased by 35.7% and is now trading at $56.38.
View which stocks have been most impacted by COVID-19.

Is ChemoCentryx a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than ChemoCentryx?

Wall Street analysts have given ChemoCentryx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ChemoCentryx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for ChemoCentryx.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $5.09 million during the quarter, compared to analysts' expectations of $12.86 million. ChemoCentryx had a negative trailing twelve-month return on equity of 17.23% and a negative net margin of 58.10%.
View ChemoCentryx's earnings history.

What price target have analysts set for CCXI?

8 equities research analysts have issued 1-year target prices for ChemoCentryx's shares. Their forecasts range from $58.00 to $119.00. On average, they expect ChemoCentryx's stock price to reach $77.13 in the next year. This suggests a possible upside of 36.8% from the stock's current price.
View analysts' price targets for ChemoCentryx or view Wall Street analyst' top-rated stocks.

Who are some of ChemoCentryx's key competitors?

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Novavax (NVAX) and Ionis Pharmaceuticals (IONS).
View all of CCXI's competitors.

What other stocks do shareholders of ChemoCentryx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR).

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:

Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 61, Pay $968.76k)
Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 57, Pay $696.65k)
Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 59, Pay $563.8k)
Ms. Kari E. Leetch, Sr. VP of HR
Dr. Catherine Lee Kelleher, Sr. VP of Clinical Devel.
Ms. Dalia R. Rayes, Sr. VP & Head of Commercial
Dr. Sangita Ghosh Ph.D., Sr. VP of Technical Operations

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by a number of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.30%), Genesee Capital Advisors LLC (0.04%), Exane Derivatives (0.03%), Strs Ohio (0.02%), Chicago Partners Investment Group LLC (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Rajinder Singh, Susan M Kanaya, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx.

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Thomas A Edwards, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx or view top insider-selling stocks.

Which major investors are buying ChemoCentryx stock?

CCXI stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Exane Derivatives, Chicago Partners Investment Group LLC, Pacer Advisors Inc., Nisa Investment Advisors LLC, and Genesee Capital Advisors LLC.
View insider buying and selling activity for ChemoCentryx or or view top insider-buying stocks.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $56.38.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $3.90 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here